M. Juliana McElrath
Fred Hutchinson Cancer Center
Public scientific profile · Unclaimed
Built from public scholarly sources. Expertise is inferred by ScienceWe from publications and has not been confirmed by the scientist.
Top expertise
HIV Research and Treatment
Strong evidence · 8 supporting papers · latest 2026
SARS-CoV-2 and COVID-19 Research
Strong evidence · 7 supporting papers · latest 2026
HIV/AIDS Research and Interventions
Strong evidence · 1 supporting paper · latest 2026
HIV/AIDS drug development and treatment
Strong evidence · 4 supporting papers · latest 2026
vaccines and immunoinformatics approaches
Strong evidence · 8 supporting papers · latest 2026
Immunotherapy and Immune Responses
Solid evidence · 5 supporting papers · latest 2026
Monoclonal and Polyclonal Antibodies Research
Solid evidence · 3 supporting papers · latest 2026
COVID-19 Clinical Research Studies
Solid evidence · 3 supporting papers · latest 2026
Publications (16)
Long-read deep sequencing reveals high rates of multilineage transmission and rapid viral population changes in acute HIV infection
2026DOIPMID 41279611
VRC01 Exerted Differential Pressure on HIV-1 Envelope From Subtypes B and C That Continued in the First Weeks Postdiagnosis in the Antibody Mediated Prevention Trials
2026DOIPMID 42708883
Relative efficacy, safety and immunogenicity of bivalent versus monovalent COVID-19 mRNA booster vaccines: a randomized trial
2026DOIPMID 42779880
Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A): a first-in-human, phase 1 randomised trial
2026DOI
Priming of Multiple HIV Neutralizing B Cell Precursors in Humans
2026DOIPMID 42145593
Coordinated immune response distinguishes duration of SARS-CoV-2 viral particle shedding in humans
2026DOI
Coordinated Immune Response Distinguishes Duration of SARS-CoV-2 Viral Particle Shedding in Humans
2026DOI
mRNA-1273 SARS-CoV-2 vaccination in people with HIV: an immune correlates analysis of CD4 + T cell responses in the multicenter CoVPN 3008 observational study
2026DOI
Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, VRC07-523LS, and PGT121.414.LS infused intravenously or subcutaneously (HVTN 140/HPTN 101 part B): a phase 1, randomised trial
2026DOIPMID 42114530
A phase 1 randomized controlled trial to evaluate the safety and immunogenicity of a HIV monomeric gp120 protein B-cell lineage targeting HIV vaccine in healthy adults
2026DOIPMID 42245034
The vaccine platform used for COVID-19 primary immunization shapes the quality of the human B cell response to a vaccine boost
2026DOIPMID 41739906
A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trials
2026DOI
The safety, reactogenicity, and immunogenicity of the self-amplifying mRNA COVID-19 vaccine GRT-R910 as a booster in healthy adults
2026DOIPMID 41740461
Coordinated immune response distinguishes duration of SARS-CoV-2 viral particle shedding in humans
2026DOIPMID 42016169
Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials
2026DOI
Organizations in sourced records
Affiliation evidence only — not confirmed current employment.
- Fred Hutchinson Cancer Center
Source: OpenAlex · retrieved 2026-09-29